Proliferative primary human sertoli cell cultures and their applications

2:

• The technology of claim 1, wherein the technology is utilized to produce cells under GMP conditions for clinical use.

3:

• Cultures comprising:
• proliferative primary human Sertoli cells.

(canceled)

5:

• The cultures of claim 3, wherein the said primary human Sertoli cells are polarized.

6:

• The cultures of claim 3, wherein the proliferative primary human Sertoli cells are transformed or genetically modified.

7-9. (canceled)

10:

• The cultures of claim 3, wherein said human is 28 years of age or younger.

11:

• The cultures of claim 3, wherein said human is 29 years of age or older.

12:

• The cultures of claim 3, wherein said cultures are used for research.

13:

• Clonal cultures that have been derived from the cultures of claim 3 by limiting dilution selection or fluorescence-assisted cell sorting (FACS).

14:

• The cultures of claim 3, wherein said cultures are provided in a pharmaceutical composition with a pharmaceutically acceptable carrier.

15:

• The pharmaceutical composition of claim 14, wherein the proliferative primary human Sertoli cells are genetically modified so as to express a recombinant protein and administered to a human for ex vivo gene therapy.

16:

• The pharmaceutical composition of claim 14, wherein the composition administered to a human for cell therapy.

17:

• The pharmaceutical composition of claim 14, wherein the composition is administered to the testes for treatment of male infertility due to lack of supporting cells.

18:

• The pharmaceutical composition of claim 14, wherein the composition is administered to a human for immunosuppressive cell therapy.

19:

• The pharmaceutical composition of claim 14, wherein the composition is administered to a human as a source of neurotrophic or growth factors.

20:

• The pharmaceutical composition of claim 14, wherein the composition is administered to a human to reduce the immune response to co-implanted allogeneic or xenogeneic cells or tissue.

21:

• The pharmaceutical composition of claim 14, wherein the composition is administered to a human to reduce an autoimmune response to co-implanted cells or tissue.

22:

• The pharmaceutical composition of claim 14, wherein the composition is administered to a human to reduce an autoimmune response to co-implanted pancreatic islets.

23:

• The pharmaceutical composition of claim 14, wherein the composition is provided in a device encapsulating the cells, and wherein said device is suitable for implantation into a mammalian subject.